Back

Time course of onset and offset of blood pressure reduction with a novel low-dose triple single pill combination

31 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Triple therapy in hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Abdul Salam Mohammad

George Institute for Global Health, Hyderabad (India)

6 More presentations in this session

Presentation thumbnail
Sex differences in response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial
Doctor P. Guimaraes (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Initial triple low-dose combination therapy improves blood pressure control without increased adverse events: a systematic review and meta-analysis
Associate Professor J. Park (Goyang, KR)
Abstract Slides Video
Presentation thumbnail
Treatment escalation beyond triple therapy in patients with resistant hypertension: a population-based observational cohort study from UK healthcare records
Doctor P. Swift (London, GB)
Abstract Slides Video
Presentation thumbnail
Impact of baseline cardiovascular risk on hypertension treatment with a novel triple single-pill: a subanalysis of the OPTION TREAT Trial
Doctor V. Madrini (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of intensive versus standard systolic blood pressure treatment: A systematic review and meta-analysis
Associate Professor O. Rueda Ochoa (Bucaramanga, CO)
Abstract Slides Video

Access the full session

Session thumbnail
Triple therapy in hypertension

The Event

Event poster

ESC Congress 2026

31 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
GMRx2 - Efficacy and safety of a novel triple single pill combination
31 August 2024
thumbnail
Congress Presentation
Physician-guided telemedical care achieves sustained blood pressure control in uncontrolled hypertension: a randomized-controlled pilot study.
29 August 2026
thumbnail
Congress Presentation
Effects of a novel low-dose triple combination on blood pressure variability: results from the TRIDENT trial
30 August 2026
thumbnail
Congress Presentation
RNA interference therapy targeting hepatic angiotensinogen for the treatment of hypertension and cardiovascular disease: a first-in-human and proof-of-concept study
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources